Acta Med. 2024, 67: 125-132

https://doi.org/10.14712/18059694.2025.9

P(A)SH Syndrome: Case Presentation and Short Update of Related Disorders

Simona Kordevaa, Alice Hristovab, Valentina Broshtilovac, Georgi Tcherneva,b

aOnkoderma – Clinic for Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
bDepartment of Dermatology and Venereology, Medical Institute of Ministry of Interior, Sofia, Bulgaria
cDepartment of Dermatology and Venereology, Military Medical Academy, Sofia, Bulgaria

Received November 3, 2024
Accepted December 22, 2024

References

1. Garcovich S, Genovese G, Moltrasio C, Malvaso D, Marzano AV. PASH, PAPASH, PsAPASH, and PASS: The autoinflammatory syndromes of hidradenitis suppurativa. Clin Dermatol. 2021 Mar–Apr; 39(2): 240–7. <https://doi.org/10.1016/j.clindermatol.2020.10.016>
2. Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016 Nov; 175(5): 882–91. <https://doi.org/10.1111/bjd.14691>
3. Maitrepierre F, Marzano AV, Lipsker D. A Unified Concept of Acne in the PAPA Spectrum Disorders. Dermatology. 2021; 237(5): 827–34. <https://doi.org/10.1159/000509874>
4. Genovese G, Moltrasio C, Garcovich S, Marzano AV. PAPA spectrum disorders. G Ital Dermatol Venereol. 2020 Oct; 155(5): 542–50.
5. Jacobs JC, Goetzl EJ. “Streaking leukocyte factor”, arthritis, and pyoderma gangrenosum. Pediatrics. 1975 Oct; 56(4): 570–8. <https://doi.org/10.1542/peds.56.4.570>
6. Smith EJ, Allantaz F, Bennett L, et al. Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review. Curr Genomics. 2010 Nov; 11(7): 519–27. <https://doi.org/10.2174/138920210793175921> <PubMed>
7. Edrees AF, Kaplan DL, Abdou NI. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) associated with hypogammaglobulinemia and elevated serum tumor necrosis factor-alpha levels. J Clin Rheumatol. 2002 Oct; 8(5): 273–5. <https://doi.org/10.1097/00124743-200210000-00009>
8. Mistry P, Carmona-Rivera C, Ombrello AK, et al. Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome. Ann Rheum Dis. 2018 Dec; 77(12): 1825–33. <https://doi.org/10.1136/annrheumdis-2018-213746> <PubMed>
9. Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment. Am J Clin Dermatol. 2017 Aug; 18(4): 555–62. <https://doi.org/10.1007/s40257-017-0265-1>
10. Fernandes SJ, Valdomir Nadaf MI, Monteiro NH, et al. Clinical and Genetic Findings of the First Report of PAPA Syndrome in Brazil. Case Reports Immunol. 2021 Dec 13; 2021: 6660937. <https://doi.org/10.1155/2021/6660937> <PubMed>
11. Schäffler H, Blattmann T, Findeisen A, Meinel FG, Meyer-Bahlburg A, Lamprecht G, Steinmüller-Magin L, Trauzeddel R, Emmert S. PAPA-Syndrom mit Morbus Crohn und primär sklerosierender Cholangitis/Autoimmunhepatitis-Overlap-Syndrom [PAPA syndrome with Crohn’s disease and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome]. Hautarzt. 2019 Feb; 70(2): 116–22. <https://doi.org/10.1007/s00105-018-4312-5>
12. Wu Y, Dowbenko D, Lasky LA. PSTPIP 2, a second tyrosine phosphorylated, cytoskeletal-associated protein that binds a PEST-type protein-tyrosine phosphatase. J Biol Chem. 1998 Nov 13; 273(46): 30487–96. <https://doi.org/10.1074/jbc.273.46.30487>
13. Tofteland ND, Shaver TS. Clinical efficacy of etanercept for treatment of PAPA syndrome. J Clin Rheumatol. 2010 Aug; 16(5): 244–5. <https://doi.org/10.1097/RHU.0b013e3181e969b9>
14. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009 Nov; 161(5): 1199–201. <https://doi.org/10.1111/j.1365-2133.2009.09404.x>
15. Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol. 2005 May–Jun; 22(3): 262–5. <https://doi.org/10.1111/j.1525-1470.2005.22320.x>
16. Lu LY, Tang XY, Luo GJ, Tang MJ, Liu Y, Yu XJ. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome in a Chinese family: A case report and review of literature. World J Clin Cases. 2021 Aug 6; 9(22): 6393–402. <https://doi.org/10.12998/wjcc.v9.i22.6393> <PubMed>
17. Sood AK, McShane DB, Googe PB, Wu EY. Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy. J Clin Immunol. 2019 Nov; 39(8): 832–5. <https://doi.org/10.1007/s10875-019-00685-6> <PubMed>
18. Geusau A, Mothes-Luksch N, Nahavandi H, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 2013 Feb; 149(2): 209–15. <https://doi.org/10.1001/2013.jamadermatol.717>
19. Sardana K, Bajaj S, Bose SK. Successful treatment of PAPA syndrome with minocycline, dapsone, deflazacort and methotrexate: a cost-effective therapy with a 2-year follow-up. Clin Exp Dermatol. 2019 Jul; 44(5): 577–9. <https://doi.org/10.1111/ced.13792>
20. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012 Mar; 66(3): 409–15. <https://doi.org/10.1016/j.jaad.2010.12.025>
21. Marzano AV, Ceccherini I, Gattorno M. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore). 2014 Dec; 93(27): e187. Erratum in: Medicine (Baltimore). 2015 Feb; 94(8): 1. Erratum in: Medicine (Baltimore). 2015 Apr; 94(15): 1.
22. Patel MS, et al. Clinico-histopathological Study of Cases of Pyoderma Gangrenosum: A Case Series. National Journal of Laboratory Medicine. 2022 Jan; 11(1): PS01–PS05.
23. Riyaz N, Sasidharanpillai S, Rahima S. Janardhanan AK. Pyoderma gangrenosum in association with microscopic colitis, idiopathic hypereosinophilic syndrome, selective IgE deficiency and diabetes mellitus. Clin Exp Dermatol. 2015 Aug; 40(6): 629–32.
24. Rawla P, Devasahayam J. Mallory-Weiss Syndrome. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books /NBK538190/.
25. Calderón-Castrat X, Bancalari-Díaz D, Román-Curto C, Romo-Melgar A, Amorós-Cerdán D, Alcaraz-Mas LA, Fernández-López E, Cañueto J. PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Br J Dermatol. 2016 Jul; 175(1): 194–8. <https://doi.org/10.1111/bjd.14383>
26. Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, Cugno M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013 Oct; 45(2): 202–10. <https://doi.org/10.1007/s12016-012-8351-x>
27. Huang J, Tsang LS, Shi W, Li J. Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome: A Case Report and Literature Review. Front Med (Lausanne). 2022 Mar 24; 9: 856786. <https://doi.org/10.3389/fmed.2022.856786> <PubMed>
28. Maione V, Perantoni M, Caravello S, Zambelli C, Calzavara-Pinton P. A case of PASH syndrome associated to testicular cancer. Dermatol Ther. 2021 Mar; 34(2): e14763. <https://doi.org/10.1111/dth.14763>
29. Murphy B, Morrison G, Podmore P. Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis. Int J Colorectal Dis. 2015 Aug; 30(8): 1139–40. <https://doi.org/10.1007/s00384-014-2110-9>
30. Brokamp G, Bechtel M, Chung C. Long-term Remission of Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome. Cutis. 2023 Jun; 111(6): E2–E6. <https://doi.org/10.12788/cutis.0797>
31. Lamiaux M, Dabouz F, Wantz M, et al. Successful combined antibiotic therapy with oral clindamycin and oral rifampicin for pyoderma gangrenosum in patient with PASH syndrome. JAAD Case Rep. 2017 Dec 18; 4(1): 17–21. <https://doi.org/10.1016/j.jdcr.2017.05.005> <PubMed>
32. Saint-Georges V, Peternel S, Kaštelan M, Brajac I. Tumor Necrosis Factor Antagonists in the Treatment of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Syndrome. Acta Dermatovenerol Croat. 2018 Jun; 26(2): 173–8.
33. Yan A, Gallardo M, Savu A, Kaffenberger B. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome: a single-institution case series with a focus on management. Arch Dermatol Res. 2024 Jun 15; 316(7): 397. <https://doi.org/10.1007/s00403-024-03125-7> <PubMed>
34. Brandao L, Moura R, Tricarico PM. Altered keratinization and vitamin D metabolism may be key pathogenetic pathways in syndromic hidradenitis suppurativa: a novel whole exome sequencing approach. J Dermatol Sci. 2020 Jul; 99(1): 17–22. <https://doi.org/10.1016/j.jdermsci.2020.05.004>
35. Staub J, Pfannschmidt N, Strohal R, Braun-Falco M, Lohse P, Goerdt S, Leverkus M. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad Dermatol Venereol. 2015 Nov; 29(11): 2243–7. <https://doi.org/10.1111/jdv.12765>
36. Sinclair R, Thirthar Palanivelu V. Tildrakizumab for the treatment of psoriasis. Expert Rev Clin Immunol. 2019 Jan; 15(1): 5–12. <https://doi.org/10.1080/1744666X.2019.1544493>
37. Kok Y, Nicolopoulos J, Varigos G, Howard A, Dolianitis C. Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic target. Australas J Dermatol. 2020 Aug; 61(3): e373–e374.
38. Gul MI, Singam V, Hanson C, Neill BC, Aires DJ, Rajpara AN. Remission of Refractory PASH Syndrome Using Ixekizumab and Doxycycline. J Drugs Dermatol. 2020 Nov 1; 19(11): 1123. <https://doi.org/10.36849/JDD.2020.1123>
39. Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol. 2019 Jun; 15(6): 589–97. <https://doi.org/10.1080/1744666X.2019.1601014>
40. Marletta DA, Barei F, Moltrasio C, Genovese G, Marzano AV. A case of PASH syndrome treated with guselkumab. Int J Dermatol. 2023 Nov; 62(11): e585–e587. <https://doi.org/10.1111/ijd.16766>
41. Abdul Rahman N, Jazmati A, Roumi Jamal B, Darwish I, Kouja D, Ishkhanian S. A complex case of PASH syndrome: pyoderma gangrenosum, acne, suppurative hidradenitis, and Crohn’s disease in a 36-year-old smoker. Ann Med Surg (Lond). 2024 Sep 5; 86(10): 6280–4. <https://doi.org/10.1097/MS9.0000000000002533> <PubMed>
42. Ead JK, Snyder RJ, Wise J, Cuffy C, Jafary H, Fischborn K. Is PASH Syndrome a Biofilm Disease? A Case Series and Review of the Literature. Wounds. 2018 Aug; 30(8): 216–23.
43. Sonbol H, Duchatelet S, Miskinyte S, Bonsang B, Hovnanian A, Misery L. PASH syndrome (pyoderma gangrenosum, acne and hidradenitis suppurativa): a disease with genetic heterogeneity. Br J Dermatol. 2018 Jan; 178(1): e17–e18. <https://doi.org/10.1111/bjd.15740>
44. Join-Lambert O, Duchatelet S, Delage M, et al. Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients. J Am Acad Dermatol. 2015 Nov; 73(5 Suppl 1): S66–S69. <https://doi.org/10.1016/j.jaad.2015.07.040>
45. Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013 Jun; 149(6): 762–4. <https://doi.org/10.1001/jamadermatol.2013.2907>
46. Gottlieb J, Madrange M, Gardair C, et al. PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens. Br J Dermatol. 2019 Oct; 181(4): 866–9. <https://doi.org/10.1111/bjd.18003>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive